Dendrobium Polysaccharides and Vancomycin Bacteria for Intestinal Treatment
Summary
The USPTO published patent application US20260108552A1 on April 23, 2026, filed by the Hong Kong Authentication Centre of Valuable Chinese Medicines (Application No. 19306545, filed August 21, 2025) covering therapeutic uses of Dendrobium polysaccharides and vancomycin-sensitive bacteria for intestinal disorders including inflammatory bowel disease.
“Disclosed are beneficial uses of Dendrobium polysaccharides, and compositions comprising them and vancomycin-sensitive bacteria for intestinal disorders.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published patent application US20260108552A1 covering Dendrobium polysaccharide compositions and vancomycin-sensitive bacteria for intestinal disorder treatment. The application discloses methods of treating inflammatory bowel disease through administration of Dendrobium polysaccharide and vancomycin-sensitive bacteria compositions.
If granted, this patent would confer exclusive rights to the Hong Kong Authentication Centre of Valuable Chinese Medicines for commercializing these therapeutic applications, potentially restricting competitor development of similar polysaccharide-based intestinal treatments until patent expiration.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Uses of Dendrobium polysaccharides and vancomycin-sensitive bacteria, and compositions containing the same
Application US20260108552A1 Kind: A1 Apr 23, 2026
Assignee
Hong Kong Authentication Centre of Valuable Chinese Medicines
Inventors
Quanbin HAN, Chuying HUO, Lifeng LI
Abstract
Disclosed are beneficial uses of Dendrobium polysaccharides, and compositions comprising them and vancomycin-sensitive bacteria for intestinal disorders. The present disclosure relates to a method of treating an intestinal disorders, such as an inflammatory bowel disease, comprising administering Dendrobium polysaccharide to an individual in need thereof. The present disclosure also relates to a method of treating an intestinal disease comprising administering vancomycin-sensitive bacteria to an individual in need thereof, wherein said individual has taken or is about to take Dendrobium polysaccharide.
CPC Classifications
A61K 31/715 A61K 35/745 A61K 36/8984 A61K 38/47 A61P 1/04 C12Y 302/01078 A61K 2035/115
Filing Date
2025-08-21
Application No.
19306545
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.